CN103893763A - Application of Vinexin-beta gene in coronary atherosclerotic heart disease - Google Patents
Application of Vinexin-beta gene in coronary atherosclerotic heart disease Download PDFInfo
- Publication number
- CN103893763A CN103893763A CN201410144058.3A CN201410144058A CN103893763A CN 103893763 A CN103893763 A CN 103893763A CN 201410144058 A CN201410144058 A CN 201410144058A CN 103893763 A CN103893763 A CN 103893763A
- Authority
- CN
- China
- Prior art keywords
- vinexin
- mice
- gene
- heart disease
- coronary atherosclerotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003143 atherosclerotic effect Effects 0.000 title claims abstract description 27
- 208000019622 heart disease Diseases 0.000 title claims abstract description 27
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 21
- 239000003112 inhibitor Substances 0.000 claims abstract description 17
- 239000003596 drug target Substances 0.000 claims abstract description 6
- 230000005961 cardioprotection Effects 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 6
- 108020004459 Small interfering RNA Proteins 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims description 3
- 230000009368 gene silencing by RNA Effects 0.000 claims description 3
- 241000699670 Mus sp. Species 0.000 abstract description 96
- 208000010125 myocardial infarction Diseases 0.000 abstract description 71
- 210000002216 heart Anatomy 0.000 abstract description 43
- 241000699666 Mus <mouse, genus> Species 0.000 abstract description 17
- 230000006870 function Effects 0.000 abstract description 17
- 230000004217 heart function Effects 0.000 abstract description 17
- 241000699660 Mus musculus Species 0.000 abstract description 15
- 238000011830 transgenic mouse model Methods 0.000 abstract description 15
- 206010007572 Cardiac hypertrophy Diseases 0.000 abstract description 14
- 206010061216 Infarction Diseases 0.000 abstract description 14
- 230000007574 infarction Effects 0.000 abstract description 14
- 230000000747 cardiac effect Effects 0.000 abstract description 6
- 238000003209 gene knockout Methods 0.000 abstract description 4
- 206010028594 Myocardial fibrosis Diseases 0.000 abstract description 3
- 230000000903 blocking effect Effects 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 230000004761 fibrosis Effects 0.000 abstract description 3
- 210000004351 coronary vessel Anatomy 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 230000002980 postoperative effect Effects 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 22
- 230000002107 myocardial effect Effects 0.000 description 16
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 12
- 210000004165 myocardium Anatomy 0.000 description 12
- 238000010586 diagram Methods 0.000 description 10
- 102000008186 Collagen Human genes 0.000 description 9
- 108010035532 Collagen Proteins 0.000 description 9
- 229920001436 collagen Polymers 0.000 description 9
- 238000004043 dyeing Methods 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 7
- 210000000115 thoracic cavity Anatomy 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 206010002091 Anaesthesia Diseases 0.000 description 6
- 230000037005 anaesthesia Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 230000000004 hemodynamic effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000003176 fibrotic effect Effects 0.000 description 5
- 229960002725 isoflurane Drugs 0.000 description 5
- 238000011813 knockout mouse model Methods 0.000 description 5
- 210000005240 left ventricle Anatomy 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000003444 anaesthetic effect Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000005003 heart tissue Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102100023479 Vinexin Human genes 0.000 description 3
- 101710187710 Vinexin Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 210000004704 glottis Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 210000002303 tibia Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 208000006029 Cardiomegaly Diseases 0.000 description 2
- 241000237970 Conus <genus> Species 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000009194 climbing Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 210000001174 endocardium Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000003208 gene overexpression Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 108700026460 mouse core Proteins 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 210000003516 pericardium Anatomy 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000013138 pruning Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 241001014327 Anodontia Species 0.000 description 1
- 208000006179 Aortic Coarctation Diseases 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 206010009807 Coarctation of the aorta Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 108091005975 Myofilaments Proteins 0.000 description 1
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 1
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 102000006463 Talin Human genes 0.000 description 1
- 108010083809 Talin Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 206010070995 Vascular compression Diseases 0.000 description 1
- 102000003970 Vinculin Human genes 0.000 description 1
- 108090000384 Vinculin Proteins 0.000 description 1
- 101900253678 Vinculin (isoform 1) Proteins 0.000 description 1
- 102300041331 Vinculin isoform 1 Human genes 0.000 description 1
- 229920001617 Vinyon Polymers 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 206010002583 anodontia Diseases 0.000 description 1
- 230000005212 anodontia Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003365 myofibril Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 210000003540 papillary muscle Anatomy 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000036391 respiratory frequency Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明公开一种Vinexin-β基因在冠状动脉粥样硬化性心脏病中的应用，属于基因的功能与应用领域。本发明以Vinexin-β基因敲除小鼠和心脏特异性Vinexin-β转基因小鼠为实验对象，通过阻断小鼠心脏左冠状动脉前降支（LAD）造成心肌梗死模型，结果表明与WT对照小鼠对比，Vinexin-β基因敲除小鼠在MI术后心脏梗死比例、心肌肥厚和纤维化的程度明显被抑制，心功能明显好转；而心脏特异性Vinexin-β转基因小鼠的心脏梗死比例、心肌肥厚和纤维化的程度明显加重，心功能明显恶化。从而发现Vinexin-β基因能够促进并加重冠状动脉粥样硬化性心脏病的发生发展。因此，Vinexin-β可作为药物靶标筛选治疗冠状动脉粥样硬化性心脏病的药物，Vinexin-β的抑制剂可用于制备治疗冠状动脉粥样硬化性心脏病的药物。
The invention discloses the application of Vinexin-beta gene in coronary atherosclerotic heart disease, which belongs to the field of gene function and application. The present invention takes Vinexin-β gene knockout mice and heart-specific Vinexin-β transgenic mice as experimental objects, and creates myocardial infarction models by blocking the left anterior descending coronary artery (LAD) of the mouse heart. The results show that compared with WT Compared with mice, the ratio of myocardial infarction, myocardial hypertrophy and fibrosis in Vinexin-β gene knockout mice were significantly inhibited after MI, and the cardiac function was significantly improved; while the ratio of cardiac infarction in cardiac-specific Vinexin-β transgenic mice , The degree of myocardial hypertrophy and fibrosis was significantly increased, and the cardiac function was significantly deteriorated. It was found that Vinexin-β gene can promote and aggravate the occurrence and development of coronary atherosclerotic heart disease. Therefore, Vinexin-β can be used as a drug target to screen a drug for treating coronary atherosclerotic heart disease, and the Vinexin-β inhibitor can be used for preparing a drug for treating coronary atherosclerotic heart disease.
Description
Technical field
The invention belongs to function and the application of gene, particularly the function and application of a kind of Vinexin-β gene in coronary atherosclerotic heart disease.
Background technology
Cardiovascular disease is commonly encountered diseases and the frequently-occurring disease of serious threat human life health, is the No.1 killer of human health.Ischemic heart desease is to cause the dead topmost reason of cardiovascular disease, myocardial infarction (myocardial infarction, MI) be the common type of ischemic heart desease, the blood supply blocking-up of cardiac muscle more than 30 minutes will cause the Ultrastructural change of each organelle and dysfunction, causes the irreversible damage of myocardial cell and even death.Within postictal a few minutes of acute myocardial infarction, the myocardial cell of ischemia central area just can be dead due to ischemia, is one of commonly encountered diseases of serious threat human health and life, and Incidence of CHD and mortality rate progressively rise in recent years." Chinese cardiovascular diseases reports 2005 " is the First China cardiovascular diseases authority report that China issues, the prevalence that has disclosed China hypertension, dyslipidemia, obesity, diabetic population increases year by year, and above-mentioned disease is coronary risk factor, coronary heart disease has become the principal disease that threatens China's people ' s health.
In Acute Stage of Myocardial Infarction, infarcted region cardiac muscle is coagulation necrosis, myocardium interstitial hyperemia, edema, companion's volume inflammatory cell infiltration.After acute stage, along with the collagen stroma of supporting myocardial cell decomposes, downright bad myocardial cell generation slippage, slough stretches attenuation subsequently, this is to cause one of early stage left ventricle dilatation reason, but not cardiac muscle interstitial in necrotic area also affects because of neuroendocrine that generation reconstruct causes the contraction of heart and diastolic function is impaired and finally cause heart failure.Cardiac muscle occurs only there is a small amount of myocardial cell generation division and proliferation after infarction, reparation cardiac muscular tissue that cannot be effective, complete, therefore, infarcted region cardiac muscle can only be by proliferation of fibrous tissue, replaced by the scar tissue without contractile function, and then cause serious arrhythmia, cardiac insufficiency or even death.How to allow increasing Coronary Heart Disease Patients obtain more effective treatment, reach and reduce its case fatality rate, the object of improving the quality of living, has become the common problem of paying close attention to of domestic and international medical circle.Therefore seem particularly important for the exploitation of the medicine of coronary atherosclerotic heart disease.
Vinexin is the important composition composition of the protein network of composition cell adhesion in conjunction with albumen vinculin (vinculin) with it, the combination of Vinexin and vinculin directly affects the formation of talin, and the adhesion of regulating cell-cell, cell-extracellular matrix, and finally affect a series of important cells behaviors such as migration, differentiation, division and the apoptosis of cell.Vinexin comprises 3 hypotypes, Vinexin-α, β and γ, the albumen of these 3 kinds of hypotypes all has three SH3 (srchomology 3) domain of SoHo (sorbinhomology) domain and C end at its N end, and molecular structure is high conservative all.Vinexin-β expresses in many places, especially very high at the expression of heart.We study the mice of finding Vinexin-β gene knockout, more responsive to the coarctation of aorta caused myocardial hypertrophy reaction of performing the operation, this shows that Vinexin-β is a very important adjusting albumen (Ke Chen in the caused myocardial remodelling of high load capacity and reaction of exhaustion, et al. Vinexin-β protects against cardiac hypertrophy by blocking the Akt-dependent signalling pathway. Basic Res Cardiol, 2013,108:338).Up to the present the content of applying in coronary atherosclerotic heart disease about Vinexin-β gene without bibliographical information in the world.
Summary of the invention
For solving defect and the deficiency of above-mentioned prior art; the object of the invention is to determine the mutual relation between expression and the coronary atherosclerotic heart disease of Vinexin-β gene; a kind of Vinexin-β application in the medicine of screening cardioprotection function as drug targets is provided, and then the application of the inhibitor that a kind of Vinexin-β is provided in the medicine of preparing cardioprotection function.
Object of the present invention is achieved through the following technical solutions:
The present invention is take Vinexin-β knock out mice and specific heart Vinexin-β transgenic mice as experimental subject, cause myocardial infarction model by blocking-up mouse heart ramus descendens anterior arteriae coronariae sinistrae (LAD), result shows compared with WT mice (matched group), Vinexin-β knock out mice mortality rate obviously reduces, infarct size obviously reduces, myocardial hypertrophy and Fibrotic degree obviously alleviate, and cardiac function is clearly better; And the mortality rate of specific heart Vinexin-β transgenic mice obviously raises, infarct size obviously increases, and myocardial hypertrophy and Fibrotic degree obviously increase the weight of.This prompting Vinexin-β has the effect that worsens cardiac function, can increase the weight of to promote myocardial infarction, myocardial hypertrophy and Fibrotic development, and novel targets and the New Policy of preventing and treating coronary atherosclerotic heart disease for research provide theoretical foundation and Clinical Basis.
Therefore, Vinexin-β gene can be used as drug target, builds In vitro cell model or the animal model of Vinexin-β gene overexpression, for screening the medicine of prevention, alleviation and/or treatment coronary atherosclerotic heart disease; Vinexin-β gene also can be used as the target gene in gene therapy, design and prepare medicine and/or the biological reagent of prevention, alleviation and/or treatment coronary atherosclerotic heart disease, reach the object of prevention, alleviation and/or treatment coronary atherosclerotic heart disease by technique for gene engineering.For example, take Vinexin-β as target gene, the double-stranded siRNA that design can disturb Vinexin-β to express, after synthesizing by chemical method, be injected into the method that human body disturbs by RNA and make Vinexin-β gene silencing treat coronary atherosclerotic heart disease; The mutant that can also design and build Vinexin-β, enters cell after injection, the effect substrate of competition Vinexin-β original shape, thus the function of inhibition Vinexin-β plays therapeutic purposes; In addition, can also be take Vinexin-β as shot design micromolecular compound inhibitor, utilize In vitro cell model or the animal model of Vinexin-β gene overexpression, by screening, find wherein can specificity to suppress the molecule of Vinexin-β, thereby provide new therapeutic molecules for the treatment of coronary atherosclerotic heart disease.
For the above-mentioned functions of Vinexin-β, provide Vinexin-β application in the medicine of screening treatment coronary atherosclerotic heart disease as drug targets.
For the above-mentioned functions of Vinexin-β, provide the inhibitor of Vinexin-β in the application of preparing in the medicine for the treatment of coronary atherosclerotic heart disease.
A medicine for cardioprotection function, the inhibitor that comprises Vinexin-β.
Treat a medicine for coronary atherosclerotic heart disease, the inhibitor that comprises Vinexin-β.
The inhibitor of described Vinexin-β is preferably the siRNA of Vinexin-β gene, the rna interference vector of Vinexin-β gene, and the antibody of Vinexin-β and other can suppress the one in inhibitor that Vinexin-β expresses.
The present invention has following advantage and effect with respect to prior art:
1. the present invention finds the new function of Vinexin-β, and Vinexin-β can worsen the effect of coronary atherosclerotic heart disease.
2. the function in deterioration coronary atherosclerotic heart disease based on Vinexin-β, is the drug provision target of development coronary atherosclerotic heart disease.
3. the inhibitor of Vinexin-β can be used for preparing the medicine of cardioprotection function and treatment coronary atherosclerotic heart disease.
Accompanying drawing explanation
Fig. 1 is the survival curve figure of each group of mice.
A is the survival curve figure of WT and Vinexin-β-KO mice;
B is the survival curve figure of NTG and Vinexin-β-TG mice;
Fig. 2 is the phenotype result figure of WT and Vinexin-β-KO mice.
A is the when statistics block diagram of heart shin ratio of mice psychosoma ratio, lung body;
B is heart tissue HE dyeing, infarction ratio and myocardial cell cross-sectional area statistics block diagram;
C is the dyeing of heart tissue Picro-Sirius red and collagen volume ration statistics block diagram; 1W refers to 1 week;
Fig. 3 is the phenotype result figure of NTG and Vinexin-β-TG mice.
A is the when statistics block diagram of heart shin ratio of mice psychosoma ratio, lung body;
B is heart tissue HE dyeing, infarction ratio and myocardial cell cross-sectional area statistics block diagram;
C is the dyeing of heart tissue Picro-Sirius red and collagen volume ration statistics block diagram; 1W refers to 1 week;
Fig. 4 is the cardiac function testing result figure of WT and Vinexin-β-KO mice.
A is ultrasound detection cardiac function result statistics block diagram;
B is that PV detects hemodynamic results statistics block diagram; 1W refers to 1 week;
Fig. 5 is the cardiac function testing result figure of NTG and Vinexin-β-TG mice.
A is ultrasound detection cardiac function result statistics block diagram;
B is that PV detects hemodynamic results statistics block diagram; 1W refers to 1 week.
The specific embodiment
Below in conjunction with embodiment and accompanying drawing, the present invention is described in further detail, but embodiments of the present invention are not limited to this.
Animal for research and raising
Age in laboratory animal: 8-10 week, body weight is at 23.5-27.5g, background is the specific heart Cre mice (WT of C57BL/6 strain, purchased from Jackson Laboratory, article No. 005650), specific heart Vinexin-β knock out mice (Vinexin-β-KO, purchased from Japanese RIKEN company, article No.: 01732), specific heart Vinexin-β transgenic mice (Vinexin-β-TG, specific heart Vinexin-β transgenic mice is built by the Li Hongliang of angiocardiopathy institute of Wuhan University professor laboratory) and non-transgenic mice (NTG, littermate control non-transgenic mice) be experimental subject.
The structure of specific heart Vinexin-β transgenic mice is as follows:
Transgene carrier builds information: amplification people Vinexin-β full-length gene (NCBI, Gene ID:10174, XM_005273370.2), cDNA is connected in to myocardial myosin heavy chain (α-MHC) promoter downstream, the sequence of structure, by the microinjection embryo's (C57BL/6J background) that is configured to be fertilized, is obtained to specific heart Vinexin-β-TG mouse.Above-mentioned transgenic mice preparation is prepared with reference to following document: Ke Chen, Lu Gao, Yu Liu, Yan Zhang, Ding-Sheng Jiang, Xiang Wei et al. Vinexin-β protects against cardiac hypertrophy by blocking the Akt-dependent signalling pathway. Basic Research in Cardiology (2013) 108:338)
Feeding environment: all experiment mices are all raised in the SPF of angiocardiopathy institute of Wuhan University level Experimental Animal Center.Mice special feed is provided by Chinese military medicine academy of science animal center.Raising condition: room temperature is between 22-24 ℃, and humidity is between 40-70%, and it is 12h that light and shade replaces lighting hours, freely drinks water and ingests.
[embodiment 1] myocardial infarction (MI) model obtains
1. laboratory animal grouping: male C57BL/6 background mice (WT), Vinexin-β knock out mice (Vinexin-β-KO) and specific heart Vinexin-β transgenic mice (Vinexin-β-TG) and non-transgenic mice (NTG), cause myocardial infarction (MI) model by ligation mouse heart ramus descendens anterior arteriae coronariae sinistrae (LAD).Be divided at random 8 groups, every group: C57BL/6 background WT mice sham operated rats (WT Sham) and MI art group (WT MI), Vinexin-β knock out mice sham operated rats (Vinexin-β-KO Sham) and MI art group (Vinexin-β-KO MI), non-transgenic mice sham operated rats (NTG Sham) and MI art group (NTG MI), specific heart Vinexin-β transgenic mice sham operated rats (Vinexin-β-TG Sham) and MI art group (Vinexin-β-TG MI).
2. MI model adopts blocking-up mouse heart ramus descendens anterior arteriae coronariae sinistrae (LAD) to cause myocardial infarction, model manipulation flow process:
The 2.1 anesthesia preserved skins of weighing: accurately take Mouse Weight (g) with electronic balance under dynamic mode, with accurately configuration 3% pentobarbital sodium solution of distilled water, shake is fully dissolved it gently, adopt 80mg/kg body weight dosage, calculate after required pentobarbital sodium liquor capacity and accurately extract respective volume solution with 1mL syringe, row intraperitoneal injection of anesthesia mice, after mice is fully anaesthetized down (about 3min), shaves except mice chest and oxter hair (fully exposing field of operation) with mice shaver.
2.2 tracheal intubatioies: after anesthesia certain hour (about 20-30min), folder toe detects reactionless can beginning and performs the operation.Open external light source, microscope switch, open respirator, set each parameter (respiratory frequency 100bpm, constant voltage 16-17mmHg), mice front tooth is fixed on self-control inclined-plane with rubber band, external light source shines to mice cervical region, ophthalmic tweezers pull-out mice tongue, regulate light-source brightness and position, now visible mice glottis is and opens and closes motion with breathing, when glottis is opened, tracheal intubation is sent into trachea along glottis, take off mice and connect respirator, observe mouse breathing situation, thorax fluctuating is consistent with respirator frequency represents that intubate is successful, can carry out lower step hands art, whole operation process maintains mouse temperature 37 ℃ of left and right with heating cushion.
2.3 open breast: mice adopts right arm reclining, fix mice extremity (left fore be positioned at right fore before fully to expose field of operation) with medical adhesive tape, with medical iodine tincture and 75% medical alcohol to the field of operation skin clean that carries out disinfection, with eye scissors, 0.5cm place under left fore cuts off skin along rib trend, successively separate fascia, the tissues such as muscle (are avoided compared with trunk as far as possible, block in advance and cut off again blood vessel if can not avoid), with microscissors in three, four intercostals are opened thoracic cavity and are fully exposed heart, pick up gently a small amount of pericardium and under left auricle, tear a little pericardium with micro-straight forceps, fully expose ramus descendens anterior arteriae coronariae sinistrae (LAD) or region.
2.4 following coronary artery occlusions: (mice LAD traveling is between left auricle and pulmonary conus to find LAD trend or possibility position under microscope, multiple for left auricle lower edge), hold and get 7-0 band pin stitching thread with anodontia needle holder, in left auricle lower edge 1mm place inserting needle, pulmonary conus branch pin, depth of needle 0.5mm, width is 1mm, suture passes from LAD below, stablize after 5s, place a length 2mm in heart surface ligation place, size is that the vinyon rod of No. 10 (requires smooth surface, size for ligature after taking out rod can vascular compression), after make a call to a slip-knot thereon, gently draw with ligation LAD(dynamics and be as the criterion can block LAD blood flow completely, rather gently not heavy), cut off the end of a thread, ligation success, visible left chamber antetheca is obviously become pale and is no longer recovered from cerise, electrocardiogram shows that sT section is raised and (or) T wave height is alarmmed or inversion is upwards monophasic curve of the back of a bow simultaneously.6-0 suture is sewed up thoracic cavity opening completely and is closed thoracic cavity, and 5ml syringe female connector pipe inserts thoracic cavity through otch, extracts 1mL gas, and smooth each layer of muscle, closes up skin incision and wouldn't sew up (Sham organizes not ligation LAD, directly closes breast).
2.5 close breast: after ligation completes, 6-0 suture is sewed up thoracic cavity opening (guaranteeing seamless, dislocation-free) completely and is closed thoracic cavity, 5mL syringe female connector pipe inserts thoracic cavity through otch, extract 1mL gas, 6-0 suture is each layer of muscle of layer-by-layer suture from inside to outside, skin incision is sewed up complete with 5-0 suture afterwards.
2.6 management after operation: postoperative close attention mice state, has or not adnormal respiration etc.After mice revives naturally, mice is taken off and take off tracheal intubation from respirator, put into clean rearging cage, fill in operation record card, put back to IVC cage and raise, pay close attention to mice postoperative status and death condition and carry out respective record.
In the process that murine myocardial infarction model is set up, Sham organizes all without dead mouse, and WT MI group has 34 mices to include experiment in, dead 17 mices in the time of 1 week (1W) after surgery; Vinexin-β-KO MI group has 21 mices to include experiment in, postoperative 1 week (1W) dead 5 mices; NTG MI group has 29 mices to include experiment in, postoperative 1 week (1W) dead 15 mices; TG MI group has 50 mices to include experiment in, postoperative 1 week (1W) dead 39 mices.
By the statistics of postoperative each group of mice survival state, can find that the mortality rate of Vinexin-β-KO MI group mice is starkly lower than its matched group WT mice, the mortality rate of Vinexin-β-TG MI is apparently higher than NTG MI group.Application software Graph Pad Prism 5 draws the survival curve (see figure 1) of each group of mice, result shows that the survival rate of Vinexin-β-KO MI is apparently higher than WT MI group, and Sham organizes without dead mouse, there is no notable difference (A), the survival rate of contrary same Vinexin-β-TG MI is starkly lower than NTG MI group (B), illustrates that Vinexin-β-KO MI group mice may be because the disappearance of Vinexin-β gene causes compared with low mortality rate.
[embodiment 2] murine myocardial infarction (MI) model heart infarction ratio, myocardial hypertrophy and fibrosis detect
1. draw materials
(1) previous work: prepare the urine cup of 10% formaldehyde that 20mL is housed in advance, and post label (mice numbering, group, type of surgery and draw materials the date).The culture dish that fills 10%KCl solution is placed in to the place that draws materials.Open analytical balance, return to zero for subsequent use, then weigh and put to death mice.
(2) draw materials: the curved tweezer of ophthalmology is clamped the vessel pedicle of auricle below, cuts heart, is placed in rapidly 10%KCl solution., after relaxing period, be placed on sterile gauze until cardiac arrest, push gently heart intracavity liquid, dip in after dry surface liquid, weigh and record, heart is put into corresponding urine cup, after fixing 48h, detect for pathology.
(3) measurement of correlation and calculating: take out mice lungs, after pruning, filter paper blots, and weighs and record.Cut off mouse hind leg tibia place skin, measure and record tibia length.Calculate the heavy ratio (HW/BW) with body weight of the heart, the heavy ratio (HW/TL) with tibia length of the heavy ratio (LW/BW) with body weight of lung and the heart.
2. pathology detect
2.1 prepare paraffin specimen section
Prepare paraffin specimen section by laboratory specialty pathology staff, main operation sequence comprises pruning heart → embedding frame processing → flowing water flushings → dehydration → transparent → waxdip → embedding → section → stand sheet → dry or toast for subsequent use afterwards.
2.2 hematoxylin-eosins (HE) dyeing
Key step is:
55 ℃ of baking 30min → dimethylbenzene 5min, 3 times → 100% ethanol 1min → 95% ethanol 1min → 70% ethanol 1min → distilled water 1min → haematoxylin solution 5min → washing 1min → 1% hydrochloride alcohol 1-3s → washing 1min → Scott liquid (sodium bicarbonate 0.35g, magnesium sulfate 2g, distilled water 100ml) 1min → washing 1min → Yihong solution 3-5min → distilled water washes away loose colour → 70% ethanol 1s → 95% ethanol 1s → 100% ethanol 30s, 3 times → dimethylbenzene 2min, 3 times → take advantage of in the not dry mounting → fume hood immediately of dimethylbenzene and dry up, microscope is taken pictures.
The calculating of heart infarction scale is as follows with reference to formula:
Complete endocardium girth × 100% of endocardium of left ventricle length/left ventricle in infarction ratio=heart infarction region
Myocardial cell cross-sectional area statistics: every pictures is selected more than 3 clear border, and core is roughly positioned at central cell, with Image-Pro Plus 6.0 software circle cell areas.
2.3 Picro-Sirius reds (PSR) dyeing
Key step is:
55 ℃ of baking 30min → dimethylbenzene 2min, 3 times → 100% ethanol 1min → 95% ethanol 1min → 70% ethanol 1min → flowing water rinses 10min → distilled water 1min → 0.2% phosphomolybdic acid 2min → 0.1% sirius red picric acid solution and drips in tissue, 90min → removal residual liquid → 0.01N hydrochloric acid 4s → 70% ethanol 1 time → 90% ethanol 1 time → 100% ethanol 30s dyes in wet box, 3 times → dimethylbenzene 2min, 3 times → take advantage of the not dry coverslip immediately of dimethylbenzene mounting, microscope is taken pictures.
PSR dyeing picture statistics: left chamber collagen volume fraction ratio=area of collagen/gross area × 100%.
HE coloration result is visible, and Sham organizes myocardium marshalling, Cytoplasm is abundant evenly, interstitial is normal; MI group part cardiac cell nucleus loss, myocardial cell are the change of cavity sample, the disorder of the visible cardiac muscular tissue in infarcted region, the disappearance of infarcted region myocardial cell, replace fibrous scar tissue.
Phenotype after WT and Vinexin-β-KO mice MI model the results are shown in Figure 2.The equal not statistically significant of difference in Sham group between HW/BW, LW/BW and the HW/TL of WT mice and KO mice; The WT mice MI HW/BW of postoperative 1 week, LW/BW, HW/TL are higher than its Sham group; Postoperative 1 week of MI, HW/BW, LW/BW and the HW/TL of KO mice all obviously reduce (A) compared with WT mice.HE stained can be observed: the substantially visible MI obvious attenuation in (1W) infarcted region in postoperative 1 week, one-tenth white and cicatrix, and it is neat, fine and close that high power microscope can be observed Sham group myocardium myo fibril cell arrangement, complete form, karyon and nucleolar structure are clear; MI group myofilament arrangement disorder, loose, myocardial cell volume obviously increases, form irregularity, karyon engrain, increase, deformity, kernel is fuzzy, and KO group is without WT group obviously; The postoperative myocardial infarction ratio of KO mice MI, myocardial cell cross-sectional area are all less than MI group WT mice, and difference has statistical significance (B).After PSR dyeing, we find that MI group myocardium of ventricle interstitial collagen content increases compared with Sham group, and collagen increases thick, and it is network-like that arrangement disorder becomes; The postoperative collagen content of KO mice MI is less compared with the postoperative increase of WT mice MI; No difference of science of statistics between Sham group (C).
Fig. 3 is the phenotype result after NTG and Vinexin-β-TG mice MI model.Same the TG mice MI HW/BW of postoperative 1 week, LW/BW and HW/TL are higher than its Sham group; The degree that HW/BW, the LW/BWL of postoperative 1 week TG mice of MI and HW/TL increase is apparently higher than NTG mice (A).HE stained shows, Sham group is all without obvious infarction, the infarction ratio of the postoperative TG mice of MI is much larger than NTG group, MI group all increases compared with the heart of Sham group, and the degree that the postoperative TG mouse heart of MI increases is much larger than NTG mice, can be observed: the postoperative myocardial cell cross-sectional area of TG mice MI is also greater than Sham group, is significantly higher than NTG mice MI group (B) simultaneously simultaneously.PSR dyeing is visible, and the postoperative myocardium interstitial collagen content of TG mice MI is much larger than NTG mice MI group (C).
[embodiment 3] myocardial infarction (MI) model mice cardiac function detects
1 ultrasound detection cardiac function
1.1 early-stage preparations
(1) anesthetic machine is prepared: first connect the intake interface on oxygen cylinder and anesthetic machine, then turn on dosing mouth seal cover on anesthetic machine, add rapidly isoflurane to tighten seal cover to safe scale.Turn on total valve on oxygen cylinder, adjust the knob of flow control valve, go out atmospheric pressure and maintain 0.2-0.3mPa.
(2) mice to be measured is prepared: mice to be detected is with isoflurane rapidly after anesthesia, and hair is shaved in left anterior pectorial region, by the mouse head of handling well stretch into anesthetis conduit pullover in, maintain the stable narcotism of mice with 1.5-2.0% isoflurane.
1.2 cardiac function detect
Mice is got left lateral position or dorsal position, and is shaving the even daubing coupling agent in hair-fields.Adopt high-frequency ultrasound in diagnosis instrument, frequency is 15MHz, selection standard papillary muscles of left ventricle minor axis tangent plane, measures mice heart rate (HR), LVED (Left Ventricular End Systolic Dimension) (LVEDd), left chamber end systolic diameter (LVESd), ejection fraction (EF) and shortening fraction (FS).
2 PV detect hemodynamics
2.1 early-stage preparations
(1) anesthetic machine is prepared: with ultrasound detection cardiac function part.
(2) mice to be measured is prepared: mice to be detected is with isoflurane rapidly after anesthesia, and hair is shaved in operation on neck district, and by wet gauze wiping unhairing.By the mouse head of handling well stretch into anesthetis conduit pullover in, to maintain depth of anesthesia, avoid anaesthetizing dark or excessively shallow with 1.5-2.0% isoflurane.
2.2 PV detect
After iodine tincture and 75% alcohol disinfecting, cut off mice skin of neck, separating muscle and soft tissue successively, and the right common carotid artery of dissociating pass two-wire ligation distal end under blood vessel, simultaneously slip-knot ligation proximal part.Cut a kerf (1/3-1/2 caliber) with vascular scissors at distal end, under stereomicroscope, Millar1.4F ultra micro conduit is inserted rapidly to right common carotid artery, wear a suture by conduit and vascular ligation simultaneously.Open proximal part slip-knot, conduit is inserted in left ventricle along right common carotid artery-ascending aorta, connect Powerlab System of organism signal.Waveform situation on observation recorder, regulates the position of conduit to make oscillogram clear and stable.The indexs such as monitoring mice heart rate (HR), ejection fraction (EF), the maximum climbing speed of left indoor pressure (dP/dt max) and the minimum climbing speed of left indoor pressure (dP/dt min).
This research application M type ultrasoundcardiogram and hemodynamics detect evaluates myocardial hypertrophy and cardiac function.From Laplace theorem: S=Pr/2h, P is intraventricular pressure, and r is heart cavity diameter, and h is heart wall thickness.In the OL situation of cardiac pressure, increase for adapting to heart acting, chamber wall thickness increases, and left chamber locular wall stress increases, and improves cardiac systolic function and plays early stage compensatory mechanism; But lasting Pressure Overload-induced, can promote myocardial hypertrophy, cause necrosis and the apoptosis of myocardial cell, contraction and/or the diastolic function of heart suffer damage, even finally develop into chronic heart failure sudden cardiac death.
Fig. 4 is the ultrasonic and PV testing result of WT and Vinexin-β-KO mice.Compared with WT Sham group, WT mice MI shows decreased cardiac function and myocardial hypertrophy for postoperative 1 week.Main manifestations is that index LVEDd, the LVESd of reflecting myocardium plumpness increases, and index EF, the FS of reflection cardiac function decline.Postoperative 1 week of MI, the degree that the index of the degree that the index of KO mouse cardiac muscle plumpness increases and reaction cardiac function declines is compared little with WT mice, no significant difference between each group of HR.Equal no difference of science of statistics (A) between Sham group WT mice and the above index of KO mice.By the detection of hemodynamic index, we observe WT mice and all reduce than its Sham group at the MI EF of postoperative 1 week, dp/dt max and dp/dt min, the degree that the postoperative EF of KO mice MI, dp/dt max and dp/dt min reduce is little compared with WT group, and have significant difference, HR organizes equal no significant difference (B) in Sham group and MI.Therefore the postoperative mouse core function compared with WT group of Vinexin-β-KO mice MI is clearly better.
Fig. 5 is the ultrasonic and PV testing result of NTG and Vinexin-β-TG mice.Postoperative 1 week of MI, compared with NTG mice, the degree that index EF, the FS of the degree that index LVEDd, the LVESd of TG mouse cardiac muscle plumpness increases and reaction cardiac function decline is greater than NTG group.Equal no difference of science of statistics (A) between Sham group NTG mice and the above index of TG mice.By the detection of hemodynamic index, we observe MI postoperative 1 week NTG mice EF, dp/dt max and dp/dt min all reduces than its Sham group, the degree that the postoperative EF of TG mice MI, dp/dt max and dp/dt min reduce is greater than NTG group, difference has statistical significance, and HR respectively organizes equal no significant difference (B).Therefore the postoperative mouse core function compared with NTG group of Vinexin-β-TG mice MI obviously worsens.
Our achievement in research shows, after Vinexin-β gene knockout, mouse heart infarction ratio, myocardial hypertrophy and Fibrotic degree are obviously low compared with WT group mice, and heart infarction ratio, myocardial hypertrophy and the Fibrotic degree of specific heart Vinexin-β transgenic mice obviously raise.Prove that Vinexin-β gene has important deterioration effect in coronary atherosclerotic heart disease model.
Above-described embodiment is preferably embodiment of the present invention; but embodiments of the present invention are not restricted to the described embodiments; other any do not deviate from change, the modification done under spirit of the present invention and principle, substitutes, combination, simplify; all should be equivalent substitute mode, within being included in protection scope of the present invention.
Claims (8)
1.Vinexin-β is the application in the medicine of screening cardioprotection function as drug targets.
2.Vinexin-β is the application in the medicine of screening treatment coronary atherosclerotic heart disease as drug targets.
The application of the inhibitor of 3.Vinexin-β in the medicine of preparing cardioprotection function.
4. a medicine for cardioprotection function, is characterized in that: the inhibitor that comprises Vinexin-β.
The application of the inhibitor of 5.Vinexin-β in the medicine of preparation treatment coronary atherosclerotic heart disease.
6. a medicine for the treatment of coronary atherosclerotic heart disease, is characterized in that: the inhibitor that comprises Vinexin-β.
7. according to the application described in claim 3 or 5, it is characterized in that: the inhibitor of described Vinexin-β is preferably the siRNA of Vinexin-β gene, the rna interference vector of Vinexin-β gene or the antibody of Vinexin-β and other can suppress the one in inhibitor that Vinexin-β expresses.
8. according to the medicine described in claim 4 or 6, it is characterized in that: the inhibitor of described Vinexin-β is preferably the siRNA of Vinexin-β gene, the rna interference vector of Vinexin-β gene or the antibody of Vinexin-β and other can suppress the one in inhibitor that Vinexin-β expresses.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410144058.3A CN103893763B (en) | 2014-04-10 | 2014-04-10 | The application of Vinexin-β gene in myocardial infarction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410144058.3A CN103893763B (en) | 2014-04-10 | 2014-04-10 | The application of Vinexin-β gene in myocardial infarction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103893763A true CN103893763A (en) | 2014-07-02 |
| CN103893763B CN103893763B (en) | 2016-05-11 |
Family
ID=50985543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410144058.3A Active CN103893763B (en) | 2014-04-10 | 2014-04-10 | The application of Vinexin-β gene in myocardial infarction |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103893763B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104087678A (en) * | 2014-07-23 | 2014-10-08 | 武汉大学 | Application of Vinexin-beta in treating cerebral apoplexy |
| CN104324391A (en) * | 2014-09-29 | 2015-02-04 | 武汉大学 | Function and application of Vinexin[beta] in treatment of atherosclerosis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1922332A (en) * | 2003-12-31 | 2007-02-28 | 宾夕法尼亚州研究基金会 | Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence |
-
2014
- 2014-04-10 CN CN201410144058.3A patent/CN103893763B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1922332A (en) * | 2003-12-31 | 2007-02-28 | 宾夕法尼亚州研究基金会 | Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence |
Non-Patent Citations (1)
| Title |
|---|
| KE CHEN ET AL: "Vinexin-β protects against cardiac hypertrophy by blocking the Akt-dependent signalling pathway", 《BASIC RES CARDIOL》, 22 February 2013 (2013-02-22), pages 1 - 14, XP035366336, DOI: doi:10.1007/s00395-013-0338-0 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104087678A (en) * | 2014-07-23 | 2014-10-08 | 武汉大学 | Application of Vinexin-beta in treating cerebral apoplexy |
| CN104087678B (en) * | 2014-07-23 | 2016-01-13 | 武汉大学 | Application of Vinexin-β in the treatment of cerebral apoplexy |
| CN104324391A (en) * | 2014-09-29 | 2015-02-04 | 武汉大学 | Function and application of Vinexin[beta] in treatment of atherosclerosis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103893763B (en) | 2016-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104107429B (en) | Function and application of SH2B adapter protein 3(SH2B3) for treating cardiac hypertrophy | |
| CN103898189A (en) | Application of signal regulatory protein alpha (SHPS-1) gene in coronary atherosclerotic heart disease | |
| CN103751804A (en) | Application of interferon regulatory factor 4 (IRF4) gene in coronary atherosclerotic heart disease | |
| CN103877576B (en) | Function and application of Caspase activation and recruitment domain 3 (Card3) gene in coronary atherosclerotic heart disease | |
| CN103893763A (en) | Application of Vinexin-beta gene in coronary atherosclerotic heart disease | |
| CN105079785B (en) | Three domain protein 32(TRIM32) treating function and application in myocardial hypertrophy | |
| CN103898190A (en) | Application of Toll-interacting protein (Tollip) gene in coronary atherosclerotic heart diseases | |
| CN104117058B (en) | Activin receptor sample kinases 7(ALK7) treating the function and application in myocardial hypertrophy | |
| CN104107430B (en) | Function and application of IkB kinase epsilon inhibitor (SIKE) in treating cardiac hypertrophy | |
| CN105251020A (en) | Function and application of ubiquitin specific protease 4 (USP4) in treating cardiac hypertrophy | |
| CN105194673A (en) | Functions and application of growth arrest-specific proteins 6 (GAS6) to treating myocardial hypertrophy | |
| CN103893781A (en) | Function and application of Dickkopf-3 (DKK3) gene in coronary atherosclerotic heart disease | |
| CN103893743A (en) | Function and application of growth differentiation factor 1 (GDF1) to coronary atherosclerotic heart disease | |
| CN103784972B (en) | The application of interferon regulatory factor 9 in myocardial ischemia/reperfusion injury | |
| CN104174011A (en) | Function and application of centrifugal force and shear force response protein 1 (RECS1) in treatment of cardiac hypertrophy | |
| CN104141012A (en) | Function and application of SH2B adapter protein 1 (SH2B1) in myocardial hypertrophy treatment | |
| CN103751783B (en) | The function of IRF1 in aorta arch constriction disease and the application of inhibitor thereof | |
| CN104107418A (en) | Function and application of Carabin for treating cardiac hypertrophy | |
| CN105194653A (en) | Application of zinc finger protein 307 (ZNF307) in treating myocardial hypertrophy | |
| CN105126079B (en) | G-protein signal transduction regulatory protein 14(RGS14) treating function and application in myocardial hypertrophy | |
| CN105194652B (en) | The Inhibitor-kappa B-alpha 3(ABIN3 that A20 is combined) treating function and application in myocardial hypertrophy | |
| CN105233254B (en) | Application of zinc finger protein 394(ZNF394) in treating myocardial hypertrophy | |
| CN106362167B (en) | TRAF-conjugated NF-kB activating factor (TANK) and application of inhibitor thereof in treating myocardial hypertrophy | |
| CN105181975B (en) | Function and application of Nulp1 (Nuclear localized protein-1) in treatment of myocardial hypertrophy | |
| CN105106944B (en) | Angiotensin converting enzyme 3（ACE3）Function and application in myocardial hypertrophy is treated |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191122 Address after: 430040 No.1, floor 1, No.17, eleven village, Changqing Garden, Dongxihu District, Wuhan City, Hubei Province (18) Patentee after: Wuhan Dafeng Biotechnology Co., Ltd Address before: 430072 Hubei Province, Wuhan city Wuchang District of Wuhan University Luojiashan Patentee before: WuHan University |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191218 Address after: 430014 3119, floor 3, building 9, Guanggu science and technology port, 18 huashiyuan North Road, Donghu New Technology Development Zone, Wuhan City, Hubei Province Patentee after: Wuhan linyijia Gene Technology Co., Ltd Address before: 430040 No.1, floor 1, No.17, eleven village, Changqing Garden, Dongxihu District, Wuhan City, Hubei Province (18) Patentee before: Wuhan Dafeng Biotechnology Co., Ltd |
|
| TR01 | Transfer of patent right | ||
| CP03 | Change of name, title or address |
Address after: 430076 room 002, 16 / F, building D2, phase III, software new town, No. 8, Huacheng Avenue, Wuhan East Lake New Technology Development Zone, Wuhan, Hubei Province Patentee after: Wuhan Huikang Gene Technology Co.,Ltd. Address before: Room 3119, 3 / F, building 9, Guanggu science and technology harbor, 18 huashiyuan North Road, Donghu New Technology Development Zone, Wuhan City, Hubei Province, 430014 Patentee before: Wuhan linyijia Gene Technology Co.,Ltd. |
|
| CP03 | Change of name, title or address |